ARID1A and breast carcinoma: Indeed, ARID1A deficiency sensitises tumour cells to PARP inhibitors in breast cancer and colorectal cancer cells in vitro and in vivo, and this sensitivity is dependent on the interaction of ARID1A with ATR [24].